Avecho Biotechnology (ASX:AVE) EBITDA Margin %: -187.26% (As of Dec. 2025)


What is Avecho Biotechnology EBITDA Margin %?

Avecho Biotechnology ASX:AVE EBITDA Margin % is -187.26% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 936 Biotechnology companies, Avecho Biotechnology ranks worse than 66.77% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Avecho Biotechnology's EBITDA for the six months ended in Dec. 2025 was A$-1.28 Mil. Avecho Biotechnology's Revenue for the six months ended in Dec. 2025 was A$0.68 Mil. Therefore, Avecho Biotechnology's EBITDA margin for the quarter that ended in Dec. 2025 was -187.26%.

Avecho Biotechnology  (ASX:AVE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Avecho Biotechnology EBITDA Margin % Related Terms

Avecho Biotechnology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology EBITDA Margin % Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -375.06 -174.63 -684.18 -257.72 -306.67

Avecho Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,544.44 -444.80 -124.81 -451.78 -187.26

ASX:AVE vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Avecho Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's EBITDA Margin % falls into.


Avecho Biotechnology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Avecho Biotechnology's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.818/1.245
=-306.67 %

Avecho Biotechnology's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.279/0.683
=-187.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -187.26% mean?
Avecho Biotechnology (ASX:AVE) has a EBITDA Margin % of -187.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #625 out of 936 companies in the Biotechnology industry, placing it in the top 66.8%.
Is Avecho Biotechnology's EBITDA Margin % too high?
Avecho Biotechnology's current EBITDA Margin % is -187.26%. Based on the distribution chart, Avecho Biotechnology ranks #625 out of 936 companies in the Biotechnology industry, which is below the industry midpoint.
How does Avecho Biotechnology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #625 out of 936 companies for EBITDA Margin %. This places Avecho Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avecho Biotechnology and its competitors. Avecho Biotechnology's current EBITDA Margin % is -187.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current EBITDA Margin % of -187.26%. The current EBITDA Margin % is -187.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current EBITDA Margin % is -187.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.